Open an account

LB Pharmaceuticals

LBRX · NASDAQ

$41.00+$2.19 (+5.64%)TodayMarket closed ·
Prev close $38.81

About LBRX

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.

Employees
27
Headquarters
New York City, New York
Listed
Sep 11, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
lbpharma.us

LBRX key statistics

Market cap
1.25B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
475.18K
Volume
388.42K
Open price
$38.88
High today
$41.42
Low today
$38.24
52 Week high
$50.16
52 Week low
$14.32

LB Pharmaceuticals (LBRX) at a glance

As of Oct 20, 2026, LB Pharmaceuticals (LBRX) shares are priced at $41.00, giving the company a market cap of 1.25B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $38.24 and $41.42. The current price is 7.2% above the day's low and 1.0% below its high.

Volume so far is 388.42K shares, in line with the average of 475.18K shares a day.

Over the past year LB Pharmaceuticals has ranged from $14.32 to $50.16, and now sits 74% of the way up that range.

LB Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 4 quarters. In Q2 FY26 it reported -$1.71 per share against an estimate of -$0.8194.

The average analyst price target is $56.21, 37.1% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

89%of 9 analyst ratings say Buy
  • Buy88.9%
  • Hold11.1%
  • Sell0.0%
Price target · 11 analystsAvg $56.21
Low
$37.37
Now
$41.00
High
$81.90

LBRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 4 quarters, by 6.6% on average.

  1. Q3 FY25: reported -$0.61 per share against an estimate of -$0.4641
  2. Q4 FY25: reported -$0.45 per share against an estimate of -$0.4565
  3. Q1 FY26: reported -$0.67 per share against an estimate of -$0.7599
  4. Q2 FY26: reported -$1.71 per share against an estimate of -$0.8194

LBRX news

  • Press releasePRNewswire

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

  • Avi Kapoor

    Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

Similar companies

Companies in the same industry as LB Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.